Change in Biotie Therapies' Annual General Meeting 2015

BIOTIE THERAPIES CORP.                  Stock Exchange Release            20 March 2015 at 9.00 am

Change in Biotie Therapies' Annual General Meeting 2015

Biotie Therapies Corp. ("Biotie") Annual General Meeting date will change from the previously announced 15 April 2015. Biotie continues to consider financing options to fully fund the tozadenant Phase 3 program to approval. The company will publish the invitation to the AGM in the next few weeks when more information on Phase 3 financing is available together with the recommendation of the Board's Nomination and Remuneration Committee for nominations of new additional board members.

Turku, 20 March 2015

Biotie Therapies Corp.

Timo Veromaa, President and CEO

For further information, please contact:
Virve Nurmi, Investor Relations Manager, Biotie Therapies Corp.
tel. +358 2 274 8900, e-mail: virve.nurmi@biotie.com

www.biotie.com

DISTRIBUTION:
NASDAQ OMX Helsinki Ltd
Main Media 

About Biotie 

Biotie is a specialized drug development company focused on products for neurodegenerative and psychiatric disorders. Biotie's development has delivered Selincro (nalmefene) for alcohol dependence, which received European marketing authorization in 2013 and is currently being rolled out across Europe by partner Lundbeck. The current development products include tozadenant for Parkinson's disease, which is transitioning into Phase 3 development, and two additional compounds which are in Phase 2 development for cognitive disorders including Parkinson's disease dementia, and primary sclerosing cholangitis (PSC), a rare fibrotic disease of the liver.